List view / Grid view
7 December 2015 | By Victoria White
By mining the DNA of patients with chronic lymphocytic leukaemia (CLL), researchers at Penn Medicine have uncovered 12 mutations that may be targetable using therapies already available for other cancers...
7 December 2015 | By Victoria White
Merck KGaA will also not be pursuing the treatment in pancreatic adenocarcinoma after the drug failed in two late-stage clinical trials...
7 December 2015 | By Cherwell Laboratories
Cherwell Laboratories, specialists in cleanroom microbiology solutions for the pharmaceutical and related industries, has once again supported Pharmig’s Annual Conference...
7 December 2015 | By Victoria White
Breakpoints of new agents are absolutely vital in standardising a global definition of resistance and the point at which increased dosages are needed...
7 December 2015 | By Victoria White
Janssen-Cilag International NV has announced data from the Phase 3 RESONATE-2 (PCYC-1115) trial that show ibrutinib (Imbruvica) was superior to chlorambucil in all efficacy endpoints measured in patients with treatment-naïve chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) aged 65 or older.
7 December 2015 | By Victoria White
The data showed Kyprolis in combination with dexamethasone significantly extended disease progression compared to bortezomib plus dexamethasone...
7 December 2015 | By Victoria White
This updated analysis of the Phase 1/2 study included 169 patients with FLT3 mutations who were treated with at least 80 mg gilteritinib (ASP2215)...
4 December 2015 | By Victoria White
Faster-acting insulin aspart is a mealtime insulin for improved control of postprandial glucose excursions and has been developed for the treatment of people with type 1 and type 2 diabetes...
4 December 2015 | By Victoria White
Amgen believes this submission is the first adalimumab biosimilar application submitted to the EMA and represents Amgen's first biosimilar to be submitted for approval in the EU...
3 December 2015 | By ChemAcademy
The FDA and EU published a lot of guidlines regarding process validation which makes it hard to keep up with all the changes...
3 December 2015 | By Victoria White
GBI Research says the market will rise at a steady CAGR of 2.9% from $9.2 billion in 2014 to $11.2 billion in 2021...
3 December 2015 | By Victoria White
TxCell has agreed with Trizell to terminate the collaboration, option, development and license agreement concerning TxCell’s lead product Ovasave...
3 December 2015 | By Victoria White
The combined company has an attractive late stage pipeline and several products at preclinical stage...
3 December 2015 | By Victoria White
NICE has published draft guidance as part of its highly specialised technologies programme that does not recommend Alexion’s asfotase alfa for treating paediatric-onset hypophosphatasia...
2 December 2015 | By Victoria White
Johnson & Johnson has announced four new public-private partnerships to significantly reduce the burden of HIV incidence, especially among adolescent girls...
